These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

396 related articles for article (PubMed ID: 9624475)

  • 1. Lysostaphin treatment of experimental methicillin-resistant Staphylococcus aureus aortic valve endocarditis.
    Climo MW; Patron RL; Goldstein BP; Archer GL
    Antimicrob Agents Chemother; 1998 Jun; 42(6):1355-60. PubMed ID: 9624475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lysostaphin treatment of experimental aortic valve endocarditis caused by a Staphylococcus aureus isolate with reduced susceptibility to vancomycin.
    Patron RL; Climo MW; Goldstein BP; Archer GL
    Antimicrob Agents Chemother; 1999 Jul; 43(7):1754-5. PubMed ID: 10390235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of Telavancin in a rabbit model of aortic valve endocarditis due to methicillin-resistant Staphylococcus aureus or vancomycin-intermediate Staphylococcus aureus.
    Madrigal AG; Basuino L; Chambers HF
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3163-5. PubMed ID: 16048918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of linezolid in treatment of experimental endocarditis caused by methicillin-resistant Staphylococcus aureus.
    Dailey CF; Dileto-Fang CL; Buchanan LV; Oramas-Shirey MP; Batts DH; Ford CW; Gibson JK
    Antimicrob Agents Chemother; 2001 Aug; 45(8):2304-8. PubMed ID: 11451689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Daptomycin is effective in treatment of experimental endocarditis due to methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus.
    Marco F; de la Mària CG; Armero Y; Amat E; Soy D; Moreno A; del Río A; Almela M; Mestres CA; Gatell JM; Jiménez de Anta MT; Miró JM;
    Antimicrob Agents Chemother; 2008 Jul; 52(7):2538-43. PubMed ID: 18426900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of telavancin in the treatment of experimental endocarditis due to glycopeptide-intermediate Staphylococcus aureus.
    Miró JM; García-de-la-Mària C; Armero Y; de-Lazzari E; Soy D; Moreno A; del Rio A; Almela M; Mestres CA; Gatell JM; Jiménez-de-Anta MT; Marco F;
    Antimicrob Agents Chemother; 2007 Jul; 51(7):2373-7. PubMed ID: 17485502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lysostaphin treatment of methicillin-resistant Staphylococcus aureus keratitis in the rabbit.
    Dajcs JJ; Hume EB; Moreau JM; Caballero AR; Cannon BM; O'Callaghan RJ
    Invest Ophthalmol Vis Sci; 2000 May; 41(6):1432-7. PubMed ID: 10798659
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of levofloxacin for experimental aortic-valve endocarditis in rabbits infected with viridans group streptococcus or Staphylococcus aureus.
    Chambers HF; Xiang Q; Liu ; Chow LL; Hackbarth C
    Antimicrob Agents Chemother; 1999 Nov; 43(11):2742-6. PubMed ID: 10543757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of ceftobiprole in a rabbit model of aortic valve endocarditis due to methicillin-resistant and vancomycin-intermediate Staphylococcus aureus.
    Chambers HF
    Antimicrob Agents Chemother; 2005 Mar; 49(3):884-8. PubMed ID: 15728879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence of less severe aortic valve destruction after treatment of experimental staphylococcal endocarditis with vancomycin and dexamethasone.
    Siaperas P; Pefanis A; Iliopoulos D; Katsarolis I; Kyroudi-Voulgari A; Donta I; Karayiannakos P; Giamarellou H
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3531-7. PubMed ID: 11709335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of linezolid alone or in combination with vancomycin for treatment of experimental endocarditis due to methicillin-resistant Staphylococcus aureus.
    Chiang FY; Climo M
    Antimicrob Agents Chemother; 2003 Sep; 47(9):3002-4. PubMed ID: 12937013
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanism and suppression of lysostaphin resistance in oxacillin-resistant Staphylococcus aureus.
    Climo MW; Ehlert K; Archer GL
    Antimicrob Agents Chemother; 2001 May; 45(5):1431-7. PubMed ID: 11302806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful treatment with moxifloxacin of experimental aortic valve endocarditis due to methicillin-resistant Staphylococcus aureus (MRSA).
    Galani L; Pefanis A; Sakka V; Iliopoulos D; Donta I; Triantafyllidi H; Skiadas I; Karayiannakos P; Giamarellou H
    Int J Antimicrob Agents; 2009 Jan; 33(1):65-9. PubMed ID: 18818055
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo activity of evernimicin (SCH 27899) against methicillin-resistant Staphylococcus aureus in experimental infective endocarditis.
    Boucher HW; Thauvin-Eliopoulos C; Loebenberg D; Eliopoulos GM
    Antimicrob Agents Chemother; 2001 Jan; 45(1):208-11. PubMed ID: 11120967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pseudomonas aeruginosa LasA protease in treatment of experimental staphylococcal keratitis.
    Barequet IS; Ben Simon GJ; Safrin M; Ohman DE; Kessler E
    Antimicrob Agents Chemother; 2004 May; 48(5):1681-7. PubMed ID: 15105121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lysostaphin is effective in treating methicillin-resistant Staphylococcus aureus endophthalmitis in the rabbit.
    Dajcs JJ; Thibodeaux BA; Hume EB; Zheng X; Sloop GD; O'Callaghan RJ
    Curr Eye Res; 2001 Jun; 22(6):451-7. PubMed ID: 11584345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo efficacy of the antimicrobial peptide ranalexin in combination with the endopeptidase lysostaphin against wound and systemic meticillin-resistant Staphylococcus aureus (MRSA) infections.
    Desbois AP; Gemmell CG; Coote PJ
    Int J Antimicrob Agents; 2010 Jun; 35(6):559-65. PubMed ID: 20206480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a mouse model of induced Staphylococcus aureus infective endocarditis.
    Gibson GW; Kreuser SC; Riley JM; Rosebury-Smith WS; Courtney CL; Juneau PL; Hollembaek JM; Zhu T; Huband MD; Brammer DW; Brieland JK; Sulavik MC
    Comp Med; 2007 Dec; 57(6):563-9. PubMed ID: 18246868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lysostaphin: an antistaphylococcal agent.
    Kumar JK
    Appl Microbiol Biotechnol; 2008 Sep; 80(4):555-61. PubMed ID: 18607587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative activity of cloxacillin and vancomycin against methicillin-susceptible Staphylococcus aureus experimental endocarditis.
    Fernández Guerrero ML; de Górgolas M
    J Antimicrob Chemother; 2006 Nov; 58(5):1066-9. PubMed ID: 16931540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.